JAG2 and pulmonary arterial hypertension: Future research should focus on clinical validation, evaluating the safety and efficacy of Jag2 inhibitors in PAH patients and exploring other molecular mechanisms that may contribute to PAH pathology for a comprehensive understanding and treatment of PAH.